Breaking News

Financial Report: Roche YTD11

Foreign exchange hurts results

YTD Revenues: 31.5 billion (-13%)

Comments: Group sales were down -12%, excluding Tamiflu. Pharmaceutical sales were 24.4 billion (-14%). Herceptin sales were up +8% and MabThera/Rituxan, up +7%. Lucentis sales were up 26%. Actemra sales jumped +86%. Professional Diagnostics business revenues were up 9%. Foreign exchange negatively impacted results by -13% due to appreciation of the Swiss franc.

All numbers reported in CHF

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters